Category: 16506-27-7

Coadministration with bendamustine restores the antitumor activity of obinutuzumab in obinutuzumab-resistant tumors was written by Yamashita-Kashima, Yoriko;Yorozu, Keigo;Fujimura, Takaaki;Kawasaki, Natsumi;Kurasawa, Mitsue;Yoshiura, Shigeki;Harada, Naoki;Kondoh, Osamu;Yoshimura, Yasushi. And the article was included in International Journal of Hematology in 2022.COA of Formula: C16H21Cl2N3O2 The following contents are mentioned in the article:

The glycoengineered, humanized anti-CD20 antibody obinutuzumab is indicated for previously untreated or relapsed/refractory CD20-pos. follicular lymphoma (FL). However, the effectiveness of obinutuzumab retreatment in relapsed/refractory FL after prior obinutuzumab-containing therapy is unclear. To address this issue, we investigated the antitumor activity of obinutuzumab plus bendamustine in obinutuzumab-resistant tumors established from a human non-Hodgkin lymphoma xenograft model. Obinutuzumab-resistant tumors (SU-DHL-4-OR-18-8) were established from an SU-DHL-4 xenograft model by repeated administration of obinutuzumab. Antitumor activity was evaluated based on tumor volume after treatment with obinutuzumab on Day 1, 8, and 15 and/or bendamustine on Day 1 and 2. Intratumoral natural killer (NK) cells/macrophages were evaluated by immunohistochem. and flow cytometry. In SU-DHL-4-OR-18-8 xenografted tumors, intratumoral NK cells/macrophages after obinutuzumab treatment were significantly decreased compared with parent tumors on Day 4. The endoplasmic reticulum stress sensor phospho-IRE1 was also decreased. In SU-DHL-4-OR-18-8 tumors, bendamustine treatment increased phospho-IRE1 on Day 4 and intratumor NK cells/macrophages on Day 10. Obinutuzumab combined with bendamustine significantly increased antitumor activity compared with each single agent on Day 29, with an increase in chemoattractant CCL6 expression on Day 10. Coadministration of bendamustine in obinutuzumab retreatment may be effective against obinutuzumab-resistant tumors. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7COA of Formula: C16H21Cl2N3O2).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. Imidazole has become an important synthon in the development of new drugs. Imidazole is incorporated into many important biological compounds. The most pervasive is the amino acid histidine, which has an imidazole side-chain. Histidine is present in many proteins and enzymes, e.g. by binding metal cofactors, as seen in hemoglobin.COA of Formula: C16H21Cl2N3O2

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Long-term outcomes of elderly hairy cell leukemia patients treated with cladribine was written by Hermel, David J.;Cheng, Brian;Bhangoo, Munveer S.;Burian, Carol;Waalen, Jill;Saven, Alan. And the article was included in Annals of Hematology in 2022.Application of 16506-27-7 The following contents are mentioned in the article:

Hairy cell leukemia (HCL) is a rare hematol. disorder characterized by pancytopenia and splenomegaly for which a single course of cladribine is highly effective in inducing complete remissions. However, there is limited real-world data on outcomes and complications among geriatric patients with HCL treated with cladribine. We conducted a retrospective review of all patients 70 years or older within the Scripps Clinic HCL Database at the time of first treatment with cladribine. Of the 45 patients meeting inclusion criteria, 32 (71%) achieved CR and 4 (9%) achieved PR. Of the 9 remaining patients, 7 achieved normalization of peripheral blood counts after a single course of cladribine (complete hematol. response, CHR) and 2 had no response. The median duration of response for all responders was 119 mo. Nine (20%) patients relapsed with a median time to first relapse of 28 mo. Ten patients subsequently developed 12 primary malignancies with an excess frequency (observed-to-expected ratio) of 0.85 (95% confidence interval, 0.48-1.49). Median overall survival for the entire cohort was 166 mo from time of HCL diagnosis and 119 mo from time of first cladribine administration. Forty patient deaths were observed; the standardized mortality ratio (observed-to-expected ratio) was 1.42 (95% confidence interval, 1.03-1.96), representing a statistically significant increase in the risk of death (P = .03). This study supports the high rate of complete and durable responses following a single course of cladribine in geriatric patients. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Application of 16506-27-7).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole is the basic core of some natural products such as histidine, purine, histamine and DNA based structures, etc. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. Many drugs contain an imidazole ring, such as certain antifungal drugs, the nitroimidazole series of antibiotics, and the sedative midazolam.Application of 16506-27-7

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network was written by Gay, Francesca;Guenther, Andreas;Offidani, Massimo;Engelhardt, Monika;Salvini, Marco;Montefusco, Vittorio;Patriarca, Francesca;Aquino, Sara;Ponisch, Wolfram;Spada, Stefano;Schub, Natalie;Gentili, Silvia;Wasch, Ralph;Corradini, Paolo;Straka, Christian;Palumbo, Antonio;Einsele, Hermann;Boccadoro, Mario;Sonneveld, Pieter;Gramatzki, Martin. And the article was included in Cancer (Hoboken, NJ, United States) in 2021.Computed Properties of C16H21Cl2N3O2 The following contents are mentioned in the article:

Combined therapy with carfilzomib, bendamustine, and dexamethasone was evaluated in this multicenter phase 1/2 trial conducted within the European Myeloma Network (EMN09 trial). Sixty-three patients with relapsed/refractory multiple myeloma who had received ≥2 lines of prior therapy were included. The phase 1 portion of the study determined the maximum tolerated dose of carfilzomib with bendamustine set at 70 mg/m² on days 1 and 8. After 8 cycles, responding patients received maintenance therapy with carfilzomib and dexamethasone until progression. On the basis of the phase 1 results, the recommended phase 2 dose for carfilzomib was 27 mg/m² twice weekly in weeks 1, 2, and 3. Fifty-two percent of patients achieved a partial response or better, and 32% reached a very good partial response or better. The clin. benefit rate was 93%. After a median follow-up of 21.9 mo, the median progression-free survival was 11.6 mo, and the median overall survival was 30.4 mo. The reported grade ≥3 hematol. adverse events (AEs) were lymphopenia (29%), neutropenia (25%), and thrombocytopenia (22%). The main nonhematol. grade ≥3 AEs were pneumonia, thromboembolic events (10%), cardiac AEs (8%), and hypertension (2%). In heavily pretreated patients who have relapsed/refractory multiple myeloma, combined carfilzomib, bendamustine, and dexamethasone is an effective treatment option administered in the outpatient setting. Infection prophylaxis and attention to patients with cardiovascular predisposition are required. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Computed Properties of C16H21Cl2N3O2).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole is a heterocyclic compound with a five-membered planar ring. It is amphoteric and highly polar. Imidazole based anticancer drug find applications in cancer chemotherapy. It is used as buffer component for purification of the histidine tagged recombinant proteins in immobilized metal-affinity chromatography (IMAC).Computed Properties of C16H21Cl2N3O2

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results of the phase III MabCute study was written by Rule, Simon;Barreto, Wolney Gois;Briones, Javier;Carella, Angelo M.;Casasnovas, Olivier;Pocock, Chris;Wendtner, Clemens-Martin;Zaja, Francesco;Robson, Susan;MacGregor, Lachlan;Tschopp, Roger R.;Nick, Sonja;Dreyling, Martin. And the article was included in Haematologica in 2022.Related Products of 16506-27-7 The following contents are mentioned in the article:

Rituximab plus chemotherapy induction followed by rituximab maintenance for up to 2 years confers a long-term benefit in terms of progression-free survival in patients with indolent non-Hodgkin lymphoma. It is not known whether further prolonged maintenance with rituximab provides addnl. benefit. The phase III MabCute study enrolled 692 patients with relapsed or refractory indolent non-Hodgkin lymphoma. Patients who responded to induction with rituximab plus chemotherapy and were still responding after up to 2 years’ initial maintenance with s.c. rituximab were randomized to extended maintenance with s.c. rituximab (n=138) or observation only (n=138). The primary endpoint of investigator-assessed progression-free survival in the randomized population was un-addressed by the end of study because of an insufficient number of events (129 events were needed for 80% power at 5% significance if approx. 330 patients were randomized). In total, there were 46 progression-free survival events, 19 and 27 in the rituximab and observation arms, resp. (P=0.410 by stratified log-rank test; hazard ratio 0.76 [95% confidence interval: 0.37-1.53]). The median progression-free survival was not reached in either randomized arm. There were no new safety signals; however, adverse events were seen slightly more frequently with rituximab than with observation during extended maintenance. Maintenance for up to 2 years with rituximab after response to initial induction therefore remains the standard of care in patients with relapsed or refractory indolent non-Hodgkin lymphoma. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Related Products of 16506-27-7).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. The pharmacophore of imidazole exists in bioactive compounds including amino acids, plant growth regulators and therapeutic agents.n increase of the alkyl chain length of the alcohols. Related Products of 16506-27-7

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Best treatment option for patients with refractory aggressive B-cell lymphoma in the CAR-T cell era: real-world evidence from GELTAMO/GETH Spanish groups was written by Bastos-Oreiro, Mariana;Gutierrez, Antonio;Reguera, Juan Luis;Iacoboni, Gloria;Lopez-Corral, Lucia;Terol, Mara Jose;Ortiz-Maldonado, Valentin;Sanz, Jaime;Guerra-Dominguez, Luisa;Bailen, Rebeca;Mussetti, Alberto;Abrisqueta, Pau;Hernani, Rafael;Luzardo, Hugo;Sancho, Juan-Manuel;Delgado-Serrano, Javier;Salar, Antonio;Grande, Carlos;Bento, Leyre;de Villambrosa, Sonia Gonzalez;Garcia-Belmonte, Daniel;Sureda, Anna;Perez-Martinez, Antonio;Barba, Pere;Kwon, Mi;Garcia-Sancho, Alejandro Martin. And the article was included in Frontiers in Immunology in 2022.Formula: C16H21Cl2N3O2 The following contents are mentioned in the article:

Real-world evidence comparing the efficacy of chimeric antigen receptor (CAR) T-cell therapy against that of the previous standard of care (SOC) for refractory large B-cell lymphoma (LBCL) is scarce. We retrospectively collected data from patients with LBCL according to SCHOLAR-1 criteria treated with com. CAR T-cell therapy in Spain (204 patients included and 192 treated, 101 with axicabtagene ciloleucel [axi-cel], and 91 with tisagenlecleucel [tisa-cel]) and compared the results with a historical refractory population of patients (n = 81) obtained from the GELTAMO-IPI study. We observed superior efficacy for CAR-T therapy (for both axi-cel and tisa-cel) over pSOC, with longer progression-free survival (PFS) (median of 5.6 vs. 4-6 mo, p ≤ 0.001) and overall survival (OS) (median of 15 vs. 8 mo, p < 0.001), independently of other prognostic factors (HR: 0.59 (95% CI: 0.44-0.80); p < 0.001 for PFS, and 0.45 (95% CI: 0.31-0.64) for OS). Within the CAR-T cohort, axi-cel showed longer PFS (median of 7.3 vs. 2.8 mo, resp., p = 0.027) and OS (58% vs. 42% at 12 mo, resp., p = 0.048) than tisa-cel. These differences were maintained in the multivariable anal. On the other hand, axi-cel was independently associated with a higher risk of severe cytokine release syndrome and neurotoxicity. Our results suggest that the efficacy of CAR-T cell therapy is superior to pSOC in the real-world setting. Furthermore, axi-cel could be superior in efficacy to tisa-cel, although more toxic, in this group of refractory patients according to SCHOLAR-1 criteria. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Formula: C16H21Cl2N3O2).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. The solubility of imidazoles in ethers is lower than that in alcohols and decreases with increasing chain length of the ethers . In contrast, the solubility of benzimidazoles in alcohols (C3–C6) is higher than in water and generally decreases with a Imidazole also acts as a microtubule destabilizing agents and inhibits topoisomerase and Cytochrome P450 Family 26 Subfamily A Member 1 (CYP26A1) enzymes.Formula: C16H21Cl2N3O2

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Treatment strategies for patients with diffuse large B-cell lymphoma was written by Poletto, Stefano;Novo, Mattia;Paruzzo, Luca;Frascione, Pio Manlio Mirko;Vitolo, Umberto. And the article was included in Cancer Treatment Reviews in 2022.SDS of cas: 16506-27-7 The following contents are mentioned in the article:

Diffuse large B-cell lymphoma (DLBCL) is nowadays a curable disease with the frontline treatment R-CHOP, but 30-40% of patients are still unresponsive or relapse thereafter. In the recent era several upcoming new options are improving the therapeutic landscape for relapsed/refractory (R/R) DLBCL setting, first of all anti-CD19 chimeric antigen receptor T-cells (CAR-T) that already represent a standard of care as third-line therapy and are rapidly moving as second-line treatment for those who are refractory or early relapse after R-CHOP. Among these new therapies, the combinations polatuzumab plus rituximab and bendamustine, tafasitamab plus lenalidomide for transplant ineligible patients, and CD3xCD20 bispecific antibodies are the most relevant, but several other agents and strategies are on the way. On the other hand, in the last 20 years, several efforts have been spent in the attempt to ameliorate the outcome over R-CHOP for the frontline treatment of DLBCL shortening the interval between the cycles or intensifying treatment or adding novel drugs to R-CHOP without success, so far. Recent studies combining the anti-CD79b antibody-drug conjugate polatuzumab vedotin plus R-CHP and the anti-BCL2 agent venetoclax plus R-CHOP showed promising results. Preliminary data of new upcoming strategies characterized by a tailored therapy based on different mol. subtypes of DLBCL are encouraging, showing a benefit over the standard R-CHOP. In this manuscript, the literature data on the landscape of new therapies available and upcoming for both frontline and R/R settings of DLBCL will be critically reviewed. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7SDS of cas: 16506-27-7).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole is a heterocyclic compound with a five-membered planar ring. It is amphoteric and highly polar. Imidazole is incorporated into many important biological compounds. The most pervasive is the amino acid histidine, which has an imidazole side-chain. Histidine is present in many proteins and enzymes, e.g. by binding metal cofactors, as seen in hemoglobin.SDS of cas: 16506-27-7

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

A unified platform enabling biomarker ranking and validation for 1562 drugs using transcriptomic data of 1250 cancer cell lines was written by Tibor Fekete, Janos;Gyorffy, Balazs. And the article was included in Computational and Structural Biotechnology Journal in 2022.Recommanded Product: 16506-27-7 The following contents are mentioned in the article:

In vitro cell line models provide a valuable resource to investigate compounds useful in the systemic chemotherapy of cancer. However, the due to the dispersal of the data into several different databases, the utilization of these resources is limited. Here, our aim was to establish a platform enabling the validation of chemoresistance-associated genes and the ranking of available cell line models. We processed four independent databases, DepMap, GDSC1, GDSC2, and CTRP. The gene expression data was quantile normalized and HUGO gene names were assigned to have unambiguous identification of the genes. Resistance values were exported for all agents. The correlation between gene expression and therapy resistance is computed using ROC test. We combined four datasets with chemosensitivity data of 1562 agents and transcriptome-level gene expression of 1250 cancer cell lines. We have set up an online tool utilizing this database to correlate available cell line sensitivity data and treatment response in a uniform anal. pipeline. We employed the established pipeline to by rank genes related to resistance against afatinib and lapatinib, two inhibitors of the tyrosine-kinase domain of ERBB2. The computational tool is useful 1) to correlate gene expression with resistance, 2) to identify and rank resistant and sensitive cell lines, and 3) to rank resistance associated genes, cancer hallmarks, and gene ontol. pathways. The platform will be an invaluable support to speed up cancer research by validating gene-resistance correlations and by selecting the best cell line models for new experiments This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Recommanded Product: 16506-27-7).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. The solubility of imidazoles in ethers is lower than that in alcohols and decreases with increasing chain length of the ethers . In contrast, the solubility of benzimidazoles in alcohols (C3–C6) is higher than in water and generally decreases with a This ring system is present in important biological building blocks, such as histidine and the related hormone histamine.Recommanded Product: 16506-27-7

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Search for risk factors influencing the occurrence of infusion reaction after initial treatment with obinutuzumab was written by Kuromatsu, Makoto;Kajita, Takashi;Taruno, Mai;Nishikawa, Yutaka;Akasaka, Takashi;Okuno, Tomoyuki. And the article was included in Iryo Yakugaku in 2021.Electric Literature of C16H21Cl2N3O2 The following contents are mentioned in the article:

Obinutuzumab, a novel glyco-engineered anti-CD20 monoclonal antibody, has been developed to have superior efficacy to rituximab. Although obinutuzumab frequently causes infusion reactions (IR) during initial administration, there have been few reports about the frequency and risk factors for IR. In this study, the author investigated the frequency of clin. relevant IR during obinutuzumab administration and explored the risk factors associated with obinutuzumab-induced IR. The author included patients who were administered obinutuzumab for CD20+ B-cell non-Hodgkin lymphoma treatment at the Department of Hematol. in Tenri Hospital from Sept. 2018 to Sept. 2020. Twenty-five patients were included (13 men and 12 women) and their median age was 68 (49 – 81 years). Nine (36%) of these patients developed IR (grade ≥ 2). Comparison of patient characteristics between IR and non-IR groups showed that the incidence of IR during obinutuzumab administration was related to soluble interleukin-2 receptor (sIL-2R) and lactate dehydrogenase (LDH) levels. The results of ROC curve anal. revealed the cut-off values of sIL-2R and LDH were 3,201 U/mL and 260 U/L, resp., and AUC of ROC curve for sIL-2R and LDH were estimated at 0.75 and 0.72, resp. The higher IR incidence was detected when sIL-2R levels exceeded 3.201 U/mL. In addition, the number of patients who developed IR at sIL-2R ≥ 3,201 U/mL and/or LDH ≥ 260 U/L was larger than that at sIL-2R ≥ 3,201 U/mL. The combined biomarker, SIL-2R and LDH may be useful for prediction of the occurrence of IR after the initial administration of obinutuzumab. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Electric Literature of C16H21Cl2N3O2).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. Many drugs contain an imidazole ring, such as certain antifungal drugs, the nitroimidazole series of antibiotics, and the sedative midazolam.Electric Literature of C16H21Cl2N3O2

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Combination brentuximab vedotin and bendamustine for pediatric patients with relapsed/refractory Hodgkin lymphoma was written by Forlenza, Christopher J.;Gulati, Nitya;Mauguen, Audrey;Absalon, Michael J.;Castellino, Sharon M.;Franklin, Anna;Keller, Frank G.;Shukla, Neerav. And the article was included in Blood Advances in 2021.SDS of cas: 16506-27-7 The following contents are mentioned in the article:

In patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL), achieving a complete metabolic response (CMR) after salvage therapy is associated with superior outcomes, and optimal treatments must be identified. The combination of brentuximab vedotin and bendamustine (BVB), although highly active in adult patients, has not been extensively evaluated in pediatric patients with R/R HL. We performed a multicenter, retrospective review of pediatric patients <21 years of age with R/R HL treated with BVB from Jan. 2016 through July 2019. Response was assessed by local radiologists according to Lugano classification criteria. Twenty-nine patients (17 relapsed, 12 refractory) with a median age of 16 years (range, 10-20) were treated with BVB and received a median of 3 cycles of therapy (range, 2-7). Patients received an infusion of 1.8 mg/kg of BV on day 1 with bendamustine 90 mg/m² on days 1 and 2 of 3-wk cycles. Nineteen patients (66) achieved a CMR (95CI, 46-82). An objective response was observed in 23 patients (objective response rate, 79; 95CI, 60-92). The most common grade 3 and 4 toxicities were hematol., and 3 patients (10) experienced grade 3 infusion reactions. Seventeen of 18 patients underwent successful mobilization and collection of stem cells. Sixteen patients (13 autologous, 3 allogeneic) received a consolidative transplant after BVB. The 3-yr post-BVB event-free and overall survival were 65(95CI, 46-85) and 89(95CI, 74-100), resp. For pediatric patients with R/R HL, BVB was well tolerated and compared favorably with currently accepted salvage regimens. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7SDS of cas: 16506-27-7).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole is the basic core of some natural products such as histidine, purine, histamine and DNA based structures, etc. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. Imidazole based anticancer drug find applications in cancer chemotherapy. It is used as buffer component for purification of the histidine tagged recombinant proteins in immobilized metal-affinity chromatography (IMAC).SDS of cas: 16506-27-7

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience was written by Stefoni, Vittorio;Argnani, Lisa;Carella, Matteo;Casadei, Beatrice;Morigi, Alice;Lolli, Ginevra;Broccoli, Alessandro;Pellegrini, Cinzia;Nanni, Laura;Coppola, Paolo Elia;Zinzani, Pier Luigi. And the article was included in Journal of Cancer Research and Clinical Oncology.HPLC of Formula: 16506-27-7 The following contents are mentioned in the article:

One of the most critical issues in the management of Hodgkin lymphoma (HL) patients who resulted as primary relapsed or refractory is to obtain a minimal disease status before autologous stem cell transplantation (ASCT). Finding a salvage regimen able to induce this status without severe toxicity would represent a major achievement in this setting. A single-center retrospective study was conducted to assess effectiveness and safety of BEGEV (bendamustine, gemcitabine, and vinorelbine) regimen as first salvage setting prior to ASCT in HL patients. Forty-three patients were treated in our institution between Oct. 2017 and Nov. 2020. Median age at BEGEV therapy was 35.0 years (range 17.2- 70.0), and the median time from frontline therapy to the first cycle of BEGEV was 79.5 days (range 4-2267). At the end of treatment, 31 patients achieved a complete response (CR), with an overall response rate of 76.7%. Forty-one patients harvested CD34+ cells and 35/43 (81.4%) patients underwent ASCT. With a median follow-up of 22 mo, 4 CR patients had disease relapse, yielding an estimated disease-free survival of 73.9% at 34 mo. The estimated 2-yr progression-free survival was 66.7%. Response to first-line chemotherapy did not significantly influence prognosis. BEGEV regimen was well tolerated, and reversible haematol. toxic effects were the most common adverse events. Real-life data on BEGEV regimen as first salvage setting showed a relevant rate of objective responses and a limited myelotoxicity with no impairment of a subsequent mobilization of peripheral blood stem cells. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7HPLC of Formula: 16506-27-7).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole is the basic core of some natural products such as histidine, purine, histamine and DNA based structures, etc. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. Imidazole is incorporated into many important biological compounds. The most pervasive is the amino acid histidine, which has an imidazole side-chain. Histidine is present in many proteins and enzymes, e.g. by binding metal cofactors, as seen in hemoglobin.HPLC of Formula: 16506-27-7

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem